Home
  • E-mailTone.Bjorge@uib.no
  • Phone+47 55 58 85 30
  • Visitor Address
    Alrek helseklynge, blokk D, Årstadveien 17
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

Tone Bjørge, MD, PhD, is professor of Epidemiology and Head of the Epidemiology and Medical Statistics Section (EPISTAT) at the Department of Global Public Health and Primary Care (IGS), Faculty of Medicine, University of Bergen. She is a cancer epidemiologist, and has a part-time researcher position at the Cancer Registry of Norway. Bjørge is heading the Academic Panel for implementation of HPV primary screening in Norway, the Steering Committee of the Janus Serum Bank, is member of the Scientific Council of WHO’s cancer agency, International Agency for Research on Cancer (IARC), and has joined the group of GBD collaborators.

Bjørge has been working in the field of cancer epidemiology for more than 25 years, and have been engaged in studying the distribution of cancer in populations, examining the validity and strengths of associations between various exposures and different cancers, evaluating the efficacy of preventive measures, and the outcome and consequences of disease.

10 selected publications

  1. Kitahara CM, Daltveit DS, Ekbom A, Engeland A, Gissler M, Glimelius I, Grotmol T, Lagerros YT, Madanat-Harjuoja L, Männistö T, Sørensen HT, Troisi R, Bjørge T. Maternal health, in utero and perinatal exposures, and risk of thyroid cancer in offspring a Nordic population-based nested case-control study. Lancet Diabetes Endocrinol 2021; 9: 94-105.
  2. Daltveit DS, Klungsøyr K, Engeland A, Ekbom A, Gissler M, Glimelius I, Grotmol T, Madanat-Harjuoja L, Ording AG, Sæther SMM, Sørensen HT, Troisi R, Bjørge T. Cancer risk in individuals with major birth defects: A large Nordic population-based case-control study among children, adolescents and adults. BMJ 2020; 371: m4060.
  3. Bjørge T, Häggström C, Ghaderi S, Nagel G, Manjer J, Tretli S, Ulmer H, Harlid S, Rosendahl AH, Lang A, Stattin P, Stocks T, Engeland A. BMI and weight changes and risk of obesity-related cancers: A pooled European cohort study. Int J Epidemiol 2019; 48: 1872-85.
  4. GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 376-93.  
  5. Stocks T, Bjørge T, Ulmer H, Manjer J, Häggström C, Nagel G, Engeland A, Johansen D, Hallmans G, Selmer R, Concin H, Tretli S, Jonsson H, Stattin P. Metabolic risk score and cancer risk: pooled analysis of seven cohorts. Int J Epidemiol 2015; 44: 1353-63.
  6. de Vogel S, Meyer K, Fredriksen Å, Ulvik A, Ueland PM, Nygård O, Vollset SE, Tell GS, Tretli S, Bjørge T. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk - a Norwegian population-based nested case-control study of 3000 cases and 3000 controls within the JANUS cohort. Int J Epidemiol 2013; 42: 201-10.
  7. Bjørge T, Lukanova A, Tretli S, Manjer J, Ulmer H, Stocks T, Selmer R, Nagel G, Almquist M, Concin H, Hallmans G, Jonsson H, Häggström C, Stattin P, Engeland A. Metabolic syndrome and ovarian cancer in the Me-Can (Metabolic syndrome and cancer) project. Int J Epidemiol 2011; 40: 1667-77.
  8. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, Lukanova A, Concin H, Tretli S, Hallmans G, Jonsson H, Stattin P. Blood glucose and risk of incident and fatal cancer in the Metabolic syndrome and Cancer project (Me-Can): Analysis of six prospective cohorts. PLoS Med 2009; 6 (12): e1000201.
  9. Engeland A, Tretli S, Bjørge T. Height, body mass index, and ovarian cancer - a follow-up of 1,1 million Norwegian women. J Natl Cancer Inst 2003; 95: 1244-8.
  10. Bjørge T, Dillner J, Anttila T, Engeland A, Hakulinen T, Jellum E, Lehtinen M, Luostarinen T, Paavonen J, Pukkala E, Sapp M, Schiller J, Youngman L, Thoresen S. Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ 1997; 315: 646-9.

 

List of publications (from CRIStin)

  • Show author(s) (2022). The role of pregnancy in maternal cancer risk: Epidemiologic evidence from the Nordic Countries Linked Birth and Cancer Registries Cohort Project. Norsk Epidemiologi. 93-100.
  • Show author(s) (2022). Sex differences in childhood cancer risk among children with major birth defects: a Nordic population-based nested case-control study. International Journal of Epidemiology. 1-16.
  • Show author(s) (2022). Maternal health, pregnancy, and offspring factors and maternal thyroid cancer risk: a Nordic population-based nested case-control study. American Journal of Epidemiology. 1-14.
  • Show author(s) (2022). Interaction of leisure-time physical activity with body mass index on the risk of obesity-related cancers: A pooled study. International Journal of Cancer. 1-10.
  • Show author(s) (2022). HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial. British Journal of Cancer. 1816-1826.
  • Show author(s) (2022). Changes in life expectancy and disease burden in Norway, 1990–2019: an analysis of the Global Burden of Disease Study 2019. The Lancet Public Health. e593-e605.
  • Show author(s) (2022). CervicalScreen Norway – A screening programme in transition. Norsk Epidemiologi. 55-60.
  • Show author(s) (2022). Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer. International Journal of Cancer. 1109-1119.
  • Show author(s) (2021). The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Oncology. 26 pages.
  • Show author(s) (2021). The Inverse Association of Body Mass Index with Lung Cancer: Exploring Residual Confounding, Metabolic Aberrations and Within-Person Variability in Smoking. Cancer Epidemiology, Biomarkers and Prevention. 1489-1497.
  • Show author(s) (2021). Prescribed drugs in 27 000 individuals after diagnosis of colorectal cancer: A population-based cohort study. Pharmacoepidemiology and Drug Safety. 1037-1048.
  • Show author(s) (2021). Metabolic factors and the risk of small intestine cancers: Pooled study of 800 000 individuals in the metabolic syndrome and cancer project. International Journal of Cancer. 66-74.
  • Show author(s) (2021). Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Respiratory Medicine. 1030-1049.
  • Show author(s) (2021). Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease study 2019. BMJ Global Health. 1-15.
  • Show author(s) (2021). Cervical cancer in women under 30 years of age in Norway: a population-based cohort study. BMC Women's Health. 8 pages.
  • Show author(s) (2021). Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncology. 24 pages.
  • Show author(s) (2020). The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. The Lancet Gastroenterology and Hepatology. 42-54.
  • Show author(s) (2020). The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 582-597.
  • Show author(s) (2020). Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. British Journal of Cancer. 1715-1723.
  • Show author(s) (2020). Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study. British Journal of Cancer. 161-166.
  • Show author(s) (2020). Maternal use of folic acid and multivitamin supplements and infant risk of birth defects in Norway, 1999–2013. British Journal of Nutrition. 316-329.
  • Show author(s) (2020). Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study. The Lancet Diabetes and Endocrinology. 94-105.
  • Show author(s) (2020). Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. The Lancet. 1160-1203.
  • Show author(s) (2020). Five insights from the Global Burden of Disease Study 2019. The Lancet. 1135-1159.
  • Show author(s) (2020). Cancer risk in individuals with major birth defects: large Nordic population based case-control study among children, adolescents, and adults. The BMJ. 14 pages.
  • Show author(s) (2020). Birthweight and all-cause mortality after childhood and adolescent leukemia: a cohort of children with leukemia from Denmark, Norway, Sweden, and Washington State. Acta Oncologica. 949-958.
  • Show author(s) (2019). The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers. International Journal of Epidemiology. 93-104.
  • Show author(s) (2019). The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 934-947.
  • Show author(s) (2019). The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 913-933.
  • Show author(s) (2019). Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk: An internal replication study of 800,000 individuals. International Journal of Cancer. 58-67.
  • Show author(s) (2019). Life expectancy and disease burden in the Nordic countries: results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. The Lancet Public Health. e658-e669.
  • Show author(s) (2019). BMI and weight changes and risk of obesity-related cancers: a pooled European cohort study. International Journal of Epidemiology. 1872-1885.
  • Show author(s) (2019). Atypical glandular lesions of the cervix and risk of cervical cancer. Acta Obstetricia et Gynecologica Scandinavica. 1-9.
  • Show author(s) (2019). Associations of pregnancy-related factors and birth characteristics with risk of endometrial cancer: A Nordic population-based case-control study. International Journal of Cancer. 1-10.
  • Show author(s) (2018). Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiology and Drug Safety. 995-1004.
  • Show author(s) (2018). The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. Journal of Internal Medicine. 430-445.
  • Show author(s) (2018). Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women. International Journal of Cancer. 3071-3082.
  • Show author(s) (2018). Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. International Journal of Cancer. 1858-1867.
  • Show author(s) (2018). Pregnancy complications and subsequent breast cancer risk in the mother: a Nordic population-based case-control study. International Journal of Cancer. 1904-1913.
  • Show author(s) (2018). Paternal characteristics associated with maternal periconceptional use of folic acid supplementation. BMC Pregnancy and Childbirth. 1-8.
  • Show author(s) (2018). Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian Mother and Child Cohort Study. British Journal of Cancer. 1028-1035.
  • Show author(s) (2018). Human papillomavirus type specific risk of progression and remission during long-term follow-up of equivocal and low-grade HPV-positive cervical smears. International Journal of Cancer. 851-860.
  • Show author(s) (2018). Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 1859-1922.
  • Show author(s) (2018). Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. . The Lancet. 1923-1994.
  • Show author(s) (2018). Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 1015-1035.
  • Show author(s) (2018). A collaborative analysis of individual participant data from 19 prospective studies assesses circulating Vitamin D and prostate cancer risk. Cancer Research. 274-285.
  • Show author(s) (2017). Suicide and violent deaths in survivors of cancer in childhood, adolescence and young adulthood-a national cohort study. International Journal of Cancer. 575-580.
  • Show author(s) (2017). Preterm births and use of medication in early adulthood: a population-based registry study. Pharmacoepidemiology and Drug Safety. 742-751.
  • Show author(s) (2017). HPV genotype profile in a Norwegian cohort with ASC-US and LSIL cytology with three year cumulative risk of high grade cervical neoplasia. Gynecologic Oncology. 111-117.
  • Show author(s) (2017). Cohort Profile Update: The Janus Serum Bank Cohort in Norway. International Journal of Epidemiology. 1101-1102f.
  • Show author(s) (2016). Supplemental folic acid in pregnancy and childhood cancer risk. British Journal of Cancer. 71-75.
  • Show author(s) (2016). Reproductive history and risk of colorectal adenocarcinoma in parous women: a Nordic population-based case–control study. British Journal of Cancer. 1416-1420.
  • Show author(s) (2016). Reproduction and marriage among male survivors of cancer in childhood, adolescence and young adulthood: a national cohort study. British Journal of Cancer. 348-356.
  • Show author(s) (2016). Long Term Association between Serum 25-Hydroxyvitamin D and Mortality in a Cohort of 4379 Men. PLOS ONE. 11 pages.
  • Show author(s) (2016). Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013. International Journal of Epidemiology.
  • Show author(s) (2016). Educational attainment among long-term survivors of cancer in childhood and adolescence: a Norwegian population-based cohort study. Journal of cancer survivorship. 87-95.
  • Show author(s) (2016). Economic independence in survivors of cancer diagnosed at a young age: A Norwegian national cohort study. Cancer. 3873-3882.
  • Show author(s) (2016). Circulating folate and vitamin B12 and risk of prostate cancer: a collaborative analysis of individual participant data from six cohorts including 6875 cases and 8104 controls. European Urology. 941-951.
  • Show author(s) (2016). Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia. Obstetrics and Gynecology. 1265-1273.
  • Show author(s) (2015). Supplemental folic acid in pregnancy and maternal cancer risk. Cancer Epidemiology. 805-811.
  • Show author(s) (2015). Results of delayed triage by HPV testing and cytology in the Norwegian Cervical Cancer Screening Programme. Acta Oncologica. 200-209.
  • Show author(s) (2015). Preeclampsia in pregnancy and later use of antihypertensive drugs. European Journal of Epidemiology (EJE). 501-508.
  • Show author(s) (2015). Metabolic risk score and cancer risk: pooled analysis of seven cohorts. International Journal of Epidemiology. 1353-1363.
  • Show author(s) (2015). Folic acid supplements and risk of oral clefts in the newborn: A population-based study. British Journal of Nutrition. 1456-1463.
  • Show author(s) (2014). Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer – a large nested case-control study within the JANUS cohort in Norway. International Journal of Cancer. 197-206.
  • Show author(s) (2014). Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology. 823-828.
  • Show author(s) (2014). Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes and Control. 151-159.
  • Show author(s) (2014). Plasma methionine, choline, betaine, and dimethylglycine in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Annals of Oncology. 1609-1615.
  • Show author(s) (2014). Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: A prospective study of 580 000 subjects within the Me-Can project. BMC Cancer. 12 pages.
  • Show author(s) (2014). A prospective study on metabolic risk factors and gallbladder cancer in the metabolic syndrome and cancer (Me-Can) collaborative study. PLOS ONE.
  • Show author(s) (2013). Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. American Journal of Clinical Nutrition. 147-154.
  • Show author(s) (2013). Total serum cholesterol and cancer incidence in the Metabolic Syndrome and Cancer Project (Me-Can). PLOS ONE. 8 pages.
  • Show author(s) (2013). The Healthy Worker Effect in Cancer Incidence Studies. American Journal of Epidemiology. 1218-1224.
  • Show author(s) (2013). Serum folate and vitamin B12 concentrations in relation to prostate cancer risk-a Norwegian population-based nested case-control study of 3000 cases and 3000 controls within the JANUS cohort. International Journal of Epidemiology. 201-210.
  • Show author(s) (2013). Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes and Control. 107-116.
  • Show author(s) (2013). Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes and Control. 151-159.
  • Show author(s) (2013). Metabolic Factors Associated with Risk of Renal Cell Carcinoma. PLOS ONE.
  • Show author(s) (2013). Increased uptake of social security benefits among long-term survivors of cancer in childhood, adolescence and young adulthood: a Norwegian population-based cohort study. British Journal of Cancer. 1525-1533.
  • Show author(s) (2013). HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway. Cancer Medicine. 182-189.
  • Show author(s) (2013). Fetal growth and childhood cancer: A population-based study. Pediatrics. E1265-E1275.
  • Show author(s) (2013). Effects of preconceptional paternal drug exposure on birth outcomes: cohort study of 340,000 pregnancies using Norwegian population-based databases. British Journal of Clinical Pharmacology. 1134-1141.
  • Show author(s) (2012). Prospective study on metabolic factors and risk of prostate cancer. Cancer. 6199-6206.
  • Show author(s) (2012). Metabolic risk factors and skin cancer in the Metabolic Syndrome and Cancer Project (Me-Can). British Journal of Dermatology. 59-67.
  • Show author(s) (2012). Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. International Journal of Cancer. 193-200.
  • Show author(s) (2012). Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can). Gynecologic Oncology. 330-335.
  • Show author(s) (2012). Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Annals of Hematology. 1519-1531.
  • Show author(s) (2012). Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in Norway. Cancer Causes and Control. 1297-1305.
  • Show author(s) (2012). Blood pressure and risk of cancer incidence and mortality in the Metabolic syndrome and cancer project. Hypertension. 802-810.
  • Show author(s) (2012). Blood pressure and other metabolic syndrome factors and risk of brain tumor in the large population-based Me-Can cohort study. Journal of Hypertension. 290-296.
  • Show author(s) (2011). Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes and Control. 291-299.
  • Show author(s) (2011). Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. European Journal of Epidemiology (EJE). 157-163.
  • Show author(s) (2011). Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). International Journal of Cancer. 1890-1898.
  • Show author(s) (2011). Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can). Annals of Oncology. 1339-1345.
  • Show author(s) (2011). Metabolic risk factors and ovarian cancer in the Metabolic syndrome and cancer project. International Journal of Epidemiology. 1667-1677.
  • Show author(s) (2011). Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes and Control. 743-751.
  • Show author(s) (2011). Metabolic Factors and the Risk of Colorectal Cancer in 580,000 Men and Women in the Metabolic Syndrome and Cancer Project (Me-Can). Cancer. 2398-2407.
  • Show author(s) (2011). Maternal birth characteristics and perinatal mortality in twin offspring. An intergenerational population-based study in Norway, 1967-2008. BJOG: An International Journal of Obstetrics and Gynaecology. 698-705.
  • Show author(s) (2011). High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • Show author(s) (2011). Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiology and Drug Safety. 243-248.
  • Show author(s) (2011). Biomarkers related to one-carbon metabolism as potential risk factors for distal colorectal adenomas. Cancer Epidemiology, Biomarkers and Prevention. 1726-1735.
  • Show author(s) (2010). Trends in incidence and mortality for triplets in Norway 1967-2006: the influence of assisted reproductive technologies. BJOG: An International Journal of Obstetrics and Gynaecology. 667-675.
  • Show author(s) (2010). Metabolic syndrome and endometrial carcinoma. American Journal of Epidemiology. 892-902.
  • Show author(s) (2010). Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiology, Biomarkers and Prevention. 1737-1745.
  • Show author(s) (2010). Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiology, Biomarkers and Prevention. 2307-2317.
  • Show author(s) (2010). Increased risk of oesophageal adenocarcinoma among upstream petroleum workers. Occupational and Environmental Medicine. 335-340.
  • Show author(s) (2010). Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). International Journal of Epidemiology. 660-667.
  • Show author(s) (2009). Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstetricia et Gynecologica Scandinavica. 1083-1089.
  • Show author(s) (2009). Increased risk of oesophageal adenocarcinoma among upstream petroleum workers. Occupational and Environmental Medicine.
  • Show author(s) (2009). Fetal down syndrome and the risk of maternal breast cancer. Epidemiology. 584-589.
  • Show author(s) (2009). Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Medicine. 14 pages.
  • Show author(s) (2008). Cancer risk in children with birth defects and in their families: A population based cohort study of 5.2 million children from Norway and Sweden. Cancer Epidemiology, Biomarkers and Prevention. 500-506.
  • Show author(s) (2008). Body mass index in adolescence in relation to cause-specific mortality: A follow-up of 230,000 Norwegian adolescents. American Journal of Epidemiology. 30-37.
  • Show author(s) (2008). Birth and parental characteristics and risk of neuroblastoma in a population-based Norwegian cohort study. British Journal of Cancer. 1165-1169.
  • Show author(s) (2007). Increasing twinning rates in Norway, 1967-2004: the influence of maternal age and assisted reproductive technology (ART). Acta Obstetricia et Gynecologica Scandinavica. 833-839.
  • Show author(s) (2007). Height and body mass index and risk of lymphohematopoietic malignancies in two million norwegian men and women. American Journal of Epidemiology. 44-52.
  • Show author(s) (2007). Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. International Journal of Cancer. 378-383.
  • Show author(s) (2006). The impact of height and body mass index on the risk of testicular cancer in 600,000 Norwegian men. Cancer Causes and Control. 983-987.
  • Show author(s) (2006). Body size and thyroid cancer in two million Norwegian men and women. British Journal of Cancer. 366-370.
  • Show author(s) (2005). Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes and Control. 987-996.
  • Show author(s) (2005). Height and body mass index in relation to cancer of the small intestine in two million Norwegian men and women. British Journal of Cancer. 807-810.
  • Show author(s) (2005). Cyclins D1, D3, E, and A in vulvar carcinoma patients. Gynecologic Oncology. 733-739.
  • Show author(s) (2004). p16(INK4a) and p21(Waf1/Cip1) expression correlates with clinical outcome in vulvar carcinomas. Gynecologic Oncology. 37-45.
  • Show author(s) (2004). Obesity in adolescence and adulthood and the risk of adult mortality. Epidemiology. 79-85.
  • Show author(s) (2004). Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. European Journal of Cancer. 1058-1065.
  • Show author(s) (2004). Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. European Journal of Cancer. 1058-1065.
  • Show author(s) (2004). Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis. Analytical Chemistry. 4406-4409.
  • Show author(s) (2004). BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. British Journal of Cancer. 1829-34.
  • Show author(s) (2003). Height, body mass index and prostate cancer: a follow-up of 950 000 Norwegian men. British Journal of Cancer. 1237-1242.
  • Show author(s) (2003). Height, body mass index and ovarian cancer: a follow-up of 1.1 million Norwegian women. Journal of the National Cancer Institute. 1244-1248.
  • Show author(s) (2002). Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. British Journal of Cancer. 61-64.
  • Show author(s) (2002). Gestational trophoblastic tumors in Norway, 1968-1997: Patient characteristics, treatment and prognosis. Gynecologic Oncology. 71-76.
  • Show author(s) (2002). Bruk av p-piller og risiko for kreft. Tidsskrift for Den norske legeforening. 1788-1790.
  • Show author(s) (2001). kan testing og vaksinering for humant papillomavirus forebygge livmorhalskreft. Tidsskrift for Den norske legeforening. 2947-2951.
  • Show author(s) (2001). Kan testing og vaksinering av humant papillomavirus forebygge livmorhalskreft? Tidsskrift for Den norske legeforening. 2947-51.
  • Show author(s) (2000). Ovarialcancerscreening. Tidsskrift for Den norske legeforening. 1440-1448.
  • Show author(s) (2000). Chlamydia trachomatis infection as a risk factor for invasive cervical carcinoma. International Journal of Cancer. 35-39.
  • Show author(s) (2000). Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. International Journal of Cancer. 35-39.
  • Show author(s) (1999). Screening mot kreft. Tidsskrift for Den norske legeforening. 1129-1136.
  • Show author(s) (1999). No excess risk of cervical carcinoma among women seropositive for both HPV 16 and HPV 6/11. International Journal of Cancer. 818-22.
  • Show author(s) (1998). Prognosis of patients with Ovarian Cancer and Borderline Tumours Diagnosed in Norway between 1954 and 1993. International Journal of Cancer. 663-670.
  • Show author(s) (1998). Prognosis of 2.800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstetricia et Gynecologica Scandinavica. 777-781.
  • Show author(s) (1998). Ovarialcancer og borderlinetumorer. Tidsskrift for Den norske legeforening. 2471-2475.
  • Show author(s) (1998). Ovarialcancer og borderlinetumorer. Tidsskrift for Den norske legeforening. 2471-2475.
  • Show author(s) (1997). Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-93. Acta Obstetricia et Gynecologica Scandinavica. 606.
  • Show author(s) (1997). Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993. International Journal of Cancer. 780-786.
  • Show author(s) (1997). Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ. British Medical Journal. 646-649.
  • Show author(s) (1997). Prospective seroepidemiologic study of human papilloma virus infection as a risk factor for invasive cervical cancer. Journal of the National Cancer Institute. 1293-1299.
  • Show author(s) (1997). Prognosis of 3,000 Patients with Epithelial Ovarian Cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Society of Pelvic Surgeons: Forty-seventh annual meeting. 35.
  • Show author(s) (1997). Ovarian Cancer-Are we making progress? European Journal of Cancer. 621.
  • Show author(s) (1997). Hormonell substitusjonsbehandling og kreft. Tidsskrift for Den norske legeforening. 2201-2207.
  • Show author(s) (1997). A Prospective, Seroepidemiological Study of the Role of Human Papillomavirus in Esophageal Cancer in Norway. Cancer Research. 3989-3992.
  • Show author(s) (1996). Reproductive variables and risk of uterine cervical cancer in Norwegian registry data. Cancer Causes and Control. 351-357.
  • Show author(s) (1996). Reproductive factors and prognosis of uterine cervical cancer in Norway. British Journal of Cancer. 1843-1846.

More information in national current research information system (CRIStin)

Improving prognosis of patients with glioblastoma: Linking health registry and clinical data to basic brain tumour research (GlioLink)

The GlioLink project will combine basic brain tumour research with nationwide population-based health registry and clinical data in order to screen brain penetrating drugs for their anti-tumour effects where the aim is to identify novel targets and develop new treatment strategies for glioblastoma.

In this project, we will, based on information from the Cancer Registry of Norway, the Norwegian Prescription Database and other national databases, investigate whether the use of antipsychotics and antidepressants is associated with a prolonged survival among patients with glioblastoma. We will also investigate whether the use of these drugs is associated with a lower risk of developing glioblastoma. Several factors that affect the prognosis for patients with glioblastoma will be investigated in supplementary analyzes of clinical data. The drugs identified in the observational studies will be tested and further developed in the laboratory. Since it is likely that the newly developed drugs will not have an effect on all patients, we will also test the effect of the drugs in tissue samples from patients with glioblastoma.

 

Nordic Countries Linked Birth and Cancer Registries Cohort Project

Complex biological mechanisms promote carcinogenesis, and there is increasing evidence that pregnancy related exposures influence foetal growth cell division and organ functioning and may have a long-lasting impact on health and disease susceptibility in the mothers and offspring. Linking health registries, such as medical birth, cancer and patient registries, and pooling of data in the Nordic countries (Denmark, Finland, Norway and Sweden) have provided opportunities to conduct epidemiologic research of pregnancy exposures and subsequent cancer development. Several studies are ongoing.

 

Metabolic Syndrome and Cancer project (Me-Can) http://me-can.se/

In 2006, cohorts from Austria, Norway and Sweden were linked to national registries in the Me-Can 1.0 project. Data from almost 600,000 men and women were used to study various metabolic factors in relation to cancer risk. The Me-Can collaboration continues within the Me-Can 2.0 project where the aim is to characterise the metabolic syndrome-cancer relationship in more detail by adding new variables from cohort questionnaires and new register linkages, and new participants from the cohorts, by updating linkages to national cancer and cause of death registers, and by implementing new statistical methods. Several studies are ongoing.

 

Long-term adverse health effects in cancer patients: Prescribing of drugs in survivors of adult-onset cancer 

In this study, we take advantage of nationwide population-based registries and databases to explore long-term adverse health effects in survivors of adult-onset cancer (≥20 years). Specifically, we aim to examine the use of prescribed drugs, as proxies for specific diseases, in cancer patients compared with the general population. In sub-analyses, we will also examine prescription of drugs shortly before and after cancer diagnosis. The linked dataset includes information from the Cancer Registry of Norway and the Norwegian Prescription Database, in addition to other national registries and databases. Prescribing of drugs may provide the most comprehensive assessment of long-term health-related outcomes among cancer survivors.

MD, consultant pathologist

PhD in cancer epidemiology

Research groups

Twitter